Last reviewed · How we verify
NCT02398383
Role of Glucagon in Glucose Control in Cystic Fibrosis Related Diabetes
EARLY_PHASE1 trial testing Oral Glucose Tolerance Test in Cystic Fibrosis in 7 participants. Completed in 22 June 2017.
22 June 2017
Quick facts
| Lead sponsor | Yale University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 7 |
| Start date | 1 March 2015 |
| Primary completion | 22 June 2017 |
| Estimated completion | 22 June 2017 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Oral Glucose Tolerance Test — full drug profile →
- Mixed Meal Tolerance Test
- Hypoglycemic Clamp
Conditions studied
- Cystic Fibrosis — all drugs for Cystic Fibrosis →
- Cystic Fibrosis Related Diabetes — all drugs for Cystic Fibrosis Related Diabetes →
Sponsor
Yale University
Who can join
Adults 12 to 45, any sex, with Cystic Fibrosis or Cystic Fibrosis Related Diabetes. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Glucagon levels
Time frame: baseline
Glucagon levels in response to to a mixed meal stimulus
Sponsor's own description
This project is designed to begin to characterize the abnormalities of glucagon secretion in subjects with cystic fibrosis related diabetes along the spectrum of glucose tolerance. Cystic fibrosis patients with normal glucose tolerance as well as cystic fibrosis related diabetes as well as control subjects will undergo an oral glucose tolerance test, mixed meal tolerance test, and one step hypoglycemic clamp. Cystic fibrosis patients will then return 12 months later to undergo repeat mixed meal tolerance test and hypoglycemic clamp test.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02398383
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Oral Glucose Tolerance Test
Trials testing the same drug.
- NCT06184373 — Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot · recruiting
- NCT06942312 — Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease · enrolling by invitation
- NCT05058690 — Artificial Intelligence to Improve Cardiometabolic Risk Evaluation Using CT Scans · NA · not yet recruiting
- NCT05867524 — Characterization of Natural IL-6 Inhibition in Healthy Individuals · NA · unknown
- NCT05440968 — Comparative Effectiveness of POC-A1c vs the Current Standard Based on OGTT for Early Detection DM2 in Colombia · NA · unknown
Other recruiting trials for Cystic Fibrosis
Currently open trials in the same condition.
- NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
- NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
- NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
- NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting
Other Yale University trials
Trials by the same sponsor.
- NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
- NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
- NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
- NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
- NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02398383 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yale University
- Last refreshed: 24 June 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02398383.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing